Cargando…

Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report

No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old mal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Yu Ri, Kim, Se Hyung, Kim, Hyun Jung, Kim, Chan Kyu, Park, Seong Kyu, Koh, Eun Suk, Hong, Dae Sik
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818621/ https://www.ncbi.nlm.nih.gov/pubmed/20089186 http://dx.doi.org/10.1186/1756-8722-3-4

Ejemplares similares

A Case of Renal Synovial Sarcoma: Complete Remission was Induced by Chemotherapy with Doxorubicin and Ifosfamide.
por: Park, Soo-Jin, et al.
Publicado: (2004)

Long-term survival in a patient with acute promyelocytic leukemia with isolated meningeal relapse
por: Kim, Se Hyung, et al.
Publicado: (2010)

Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as secondline therapy for patients with advanced urothelial cancer
por: Zhang, Sheng, et al.
Publicado: (2016)

Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial)
por: Kang, Min Kyu, et al.
Publicado: (2023)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
por: Lee, Jii Bum, et al.
Publicado: (2020)

A controversial conclusion regarding primary extranodal diffuse large B-cell lymphoma
por: Park, Seong Kyu, et al.
Publicado: (2011)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Phase II Clinical Trial of Genexol® (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
por: Kim, Han Jo, et al.
Publicado: (2011)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX
por: Oh, Sung Yong, et al.
Publicado: (2016)

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
por: Lee, Suee, et al.
Publicado: (2013)

Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
por: Ji, Young Sok, et al.
Publicado: (2016)

Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?
por: Park, Jin, et al.
Publicado: (2020)

Cytological Findings of the Micropapillary Variant of Urothelial Carcinoma: A Comparison with Typical High-Grade Urothelial Carcinoma
por: Kim, Kyu-Ho, et al.
Publicado: (2013)

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
por: Keam, Bhumsuk, et al.
Publicado: (2008)

Safety and Effectiveness of Central Venous Catheterization in Patients with Cancer: Prospective Observational Study
por: Kim, Hyun Jung, et al.
Publicado: (2010)

Pathophysiological Role of Hormones and Cytokines in Cancer Cachexia
por: Kim, Hyun Jung, et al.
Publicado: (2012)

The incidence of venous thromboembolism is not lowin Korean patients with advanced pancreatic cancer
por: Yoon, Seug Yun, et al.
Publicado: (2018)

Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
por: Kim, Han Jo, et al.
Publicado: (2011)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Effects of Complete Bladder Cuff Removal on Oncological Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
por: Ryoo, Hyunsoo, et al.
Publicado: (2021)

Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
por: Kwon, Ji Yeon, et al.
Publicado: (2011)

Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study
por: Kim, Hyung Suk, et al.
Publicado: (2020)

Result of Surgical Resection for Pulmonary Metastasis from Urothelial Carcinoma
por: Han, Woo Sik, et al.
Publicado: (2012)

Long-Term Evaluation of the Lip and Nose in Bilateral Complete Cleft Lip Patients following Lip Adhesion and Secondary Nose Correction
por: Kim, Ryuck Seong, et al.
Publicado: (2022)

The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
por: Oh, Sung Yong, et al.
Publicado: (2013)

Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy
por: Lee, Kwang Suk, et al.
Publicado: (2015)

Second-Line Systemic Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
por: Yoon, Hyun Sik, et al.
Publicado: (2019)

Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX
por: Park, Hye Eun, et al.
Publicado: (2021)

Transcriptional Profiling of Advanced Urothelial Cancer Predicts Prognosis and Response to Immunotherapy
por: Baek, Seung-Woo, et al.
Publicado: (2020)

Insecticide Susceptibility of Field-Collected Populations of Culex tritaeniorhynchus in the Republic of Korea
por: Yoo, Dae-Hyun, et al.
Publicado: (2013)

FAM83H and Nectin1 expression are related with survival and relapse of bladder urothelial carcinoma patients
por: Ahn, Ae-Ri, et al.
Publicado: (2021)

A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis
por: Lee, Dong Hyun, et al.
Publicado: (2011)

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
por: Han, S-W, et al.
Publicado: (2009)

Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers
por: Lim, Sung Hee, et al.
Publicado: (2023)

Outbreak of Sudden Cardiac Deaths in a Tire Manufacturing Facility: Can It Be Caused by Nanoparticles?
por: Kim, Eun-A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nsan9r5f6qajdnrlucnd36kgo1